A new study published in The Lancet Neurology shows that an experimental anti-amyloid drug has significantly reduced the risk of Alzheimer's disease in genetically predisposed individuals. The research involved 73 participants, with half of them receiving the drug for an average of eight years. Findings indicate that among those without cognitive problems at the study's start, the treatment halved the risk of symptom development. This presents promising prospects for targeting more prevalent Alzheimer's forms seen in older adults.
The study shows that an experimental anti-amyloid drug can significantly reduce the risk of developing Alzheimer's in individuals genetically predisposed to the disease.
This research highlights the potential for future treatments aimed at more common forms of Alzheimer's, building on the understanding of amyloid's role in the condition.
Collection
[
|
...
]